Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2023 After Market Close on September 6, 2022
Avid Bioservices (NASDAQ:CDMO) will report its Q1 fiscal 2023 financial results on September 6, 2022, after market closure. The company, specializing in biologics contract development and manufacturing, aims to enhance patient lives by offering high-quality services to biotech and pharmaceutical firms. A webcast will occur at 1:30 PM Pacific Time to discuss these results and recent corporate developments, showcasing Avid's extensive experience over 29 years in manufacturing monoclonal antibodies and recombinant proteins.
- Scheduled Q1 fiscal 2023 results announcement on September 6, 2022.
- Longstanding industry experience of 29 years in biologics manufacturing.
- None.
TUSTIN, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2023 on September 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.
About Avid Bioservices, Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com
FAQ
When will Avid Bioservices report its Q1 fiscal 2023 financial results?
What time is the Avid Bioservices Q1 results webcast?
What services does Avid Bioservices provide to the biotech industry?
What is Avid Bioservices' experience in biologics manufacturing?
